Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
7,599.96
(
0.26%
)
US TECH 100
29,689.60
(
-0.07%
)
Dow Jones
51,078.88
(
0.09%
)
Brent Oil
92.54
(
-3.57%
)
Bitcoin
69,549.00
(
-2.55%
)
News Focus
News Focus
Post# of 828661
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (5) Keep Next 10 Report Keyboard Shortcuts
Replies (5) Next 10 Prev Next

StonkMaster

Send PM Follow Ignore
Followers 42
Posts 3933
Boards Moderated 0
Alias Born 12/07/2020

StonkMaster

Re: newman2021 post# 695177

Friday, 05/31/2024 11:14:50 AM

Friday, May 31, 2024 11:14:50 AM

Post# of 828661
"A meeting was held between NICE and the company in early-February regarding next steps for the appraisal of DCVax-L for treating glioblastoma, and more information will be available in due course. NICE will continue liaising with the company and monitoring timelines."

The next step is for NWBO to send in their evidence submission.

Directly from NICE, dated today:

"The next step would be for the company to let us know when they would be able to send an evidence submission to NICE. There is no further update at present."
Public Reply Private Reply New Post
Keep Last Read
Replies (5) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (5) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News